How CBD Businesses Can Make Responsible Health Claims

CBD businesses operate in a complicated regulatory environment. A claim may sound cautious, appear scientifically plausible and still create problems if it misrepresents the evidence or places the product into an unlawful regulatory category.

Responsible marketing begins before copywriting. A company must first determine what type of product it is selling, whether that product can lawfully be marketed in each jurisdiction and what evidence supports every express or implied claim.

A disclaimer, certificate of analysis or scientific citation cannot rescue an unlawful product category or unsupported promise.

Editorially reviewed by: A to Zen Therapies Editorial Team in accordance with our Editorial Policy.

This article provides general educational information about US federal marketing principles. It is not legal advice. CBD businesses should obtain advice covering their products, claims and sales jurisdictions.

Product category, scientific evidence and the overall impression of the advertising all affect whether a CBD claim is responsible.

Quick Answer

CBD businesses should avoid claims that an unapproved product diagnoses, treats, mitigates, cures or prevents a disease. Every health-related statement—including implied claims, testimonials and influencer content—needs evidence appropriate to the specific product, dose, audience and promised outcome.

Companies must also consider the product’s underlying legal status. The US Food and Drug Administration currently maintains that CBD cannot lawfully be marketed as a dietary supplement or added to conventional food in interstate commerce. Careful wording does not remove that separate federal issue.

What Is a Responsible CBD Health Claim?

A responsible CBD health claim is truthful, not misleading, appropriately qualified and supported by evidence that matches what consumers are likely to understand from the advertisement. It must also be suitable for the product’s lawful regulatory category. A well-substantiated claim does not make an otherwise prohibited product legal.

Key Takeaways

• Establish the product’s legal category before writing marketing copy.

• FDA and FTC rules address different but overlapping issues.

• FDA currently excludes CBD from the federal dietary-supplement definition.

• Disease-treatment claims can cause an unapproved CBD product to be treated as an unapproved drug.

• Cautious phrases such as “supports sleep” still require substantiation.

• A study on isolated CBD may not support a claim for a low-dose, multi-ingredient gummy.

• Testimonials and reviews create claims; they are not evidence.

• Disclaimers cannot contradict the main message of an advertisement.

• Batch testing verifies selected quality measures, not clinical effectiveness.

• Websites, affiliates, social posts, metadata and emails should be included in every compliance audit.

Table of Contents

1. Check the Product Category Before Making Claims

2. Understand Express and Implied CBD Claims

3. What the FTC Requires for Health-Claim Substantiation

4. How to Write More Responsible CBD Benefit Statements

5. Control Testimonials, Reviews and Affiliate Marketing

6. Use CBD Labels and Laboratory Reports Transparently

7. Audit Everything Customers Can See

8. Build a Substantiation File for Every Claim

9. Frequently Asked Questions

Check the Product Category Before Making Claims

The most important correction to many CBD compliance guides is that CBD should not simply be treated as an ordinary dietary-supplement ingredient.

The FDA’s current cannabis and CBD guidance states that CBD products may violate federal law when marketed as dietary supplements, added to conventional food or promoted with

claims that they prevent, diagnose, treat or cure disease.

FDA’s position is based partly on provisions that exclude an ingredient from the dietary-supplement definition when it was first investigated or approved as a drug, unless qualifying prior food or supplement marketing can be established. FDA has concluded that the

required exception has not been demonstrated for CBD.

The agency has approved one prescription CBD medicine, Epidiolex, for particular seizure disorders. This approval does not extend to retail CBD oils, gummies, drinks, cosmetics or pet products.

How Federal Treatment Differs by Product Type

Oral CBD products sold as supplements: FDA currently maintains that CBD cannot lawfully be marketed federally as a dietary supplement.

Food and beverages containing added CBD: FDA states that adding CBD to conventional food introduced into interstate commerce is prohibited under current federal law.

CBD cosmetics: Cosmetics must comply with cosmetic safety and labelling requirements. A topical product promoted as treating pain, arthritis, eczema or another condition may be regulated as a drug because of its intended use.

CBD medicines: Products intended to diagnose, treat, mitigate, cure or prevent disease generally require an approved drug application before interstate marketing.

Hemp-seed food ingredients: Certain hulled hemp seed, hemp-seed protein and hemp-seed oil ingredients have a separate FDA status. This does not authorise adding concentrated CBD to food.

State cannabis and hemp programmes may permit products that still raise federal issues. Businesses therefore need both federal and state-specific review.

Why the Supplement Disclaimer Is Not a CBD Safe Harbour

Lawful dietary supplements making qualifying structure-and-function statements generally use the familiar disclaimer explaining that FDA has not evaluated the statement and that the product is not intended to diagnose, treat, cure or prevent disease.

That rule does not make CBD a lawful dietary-supplement ingredient. It also does not neutralise a disease claim.

Printing the disclaimer beneath “CBD treats insomnia” does not change the message or prevent the product from being presented as a drug. The FDA’s structure-and-function guidance applies within the relevant lawful product framework; it is not universal permission to make health claims.

📊 Evidence Snapshot

• FDA states that CBD cannot currently be marketed federally as a dietary supplement.

• FDA also prohibits introducing conventional food containing added CBD into interstate commerce under its current interpretation.

• Only one CBD-containing prescription drug has received FDA approval.

• FTC generally expects randomised, controlled human clinical testing for health-benefit claims.

• In 2020, the FTC brought cases against six CBD sellers over unsupported disease and health claims.

• State permission to sell a hemp product does not remove separate federal advertising or product-category concerns.

Understand Express and Implied CBD Claims

Regulators assess the advertisement’s net impression—what an ordinary consumer is likely to understand from the entire presentation.

An express claim states the promise directly:

• “CBD treats arthritis.”

• “Reduces cancer symptoms.”

• “Prevents Alzheimer’s disease.”

• “Controls anxiety disorders.”

An implied claim communicates the same idea indirectly through surrounding elements.

Examples include:

• A product named “Arthritis Relief CBD”

• A testimonial describing recovery from multiple sclerosis

• An image of painful joints beside a topical CBD product

• A blog about treating insomnia linked directly from a “Buy CBD Gummies” button

• A category titled “CBD for Depression”

• Physician imagery suggesting medical approval

• Search metadata describing a product as a treatment

• Hashtags naming diseases

• Before-and-after images

• A comparison with prescription medicine

A company cannot separate the headline from the images, customer reviews or surrounding content. Regulators and consumers interpret them together.

What the FTC Requires for Health-Claim Substantiation

The FTC requires advertisers to possess a reasonable basis for objective claims before publishing them.

Its Health Products Compliance Guidance explains that substantiating health benefits will generally require randomised, controlled human clinical testing that meets accepted professional standards.

A citation is not enough by itself. The supporting research should be evaluated for:

• Study design

• Sample size

• Duration

• Appropriate controls

• Participant characteristics

• Dose

• Formulation and delivery method

• Outcome measures

• Statistical analysis

• Clinical relevance

• Consistency with the wider evidence

• Risk of bias

• Relevance to the advertised product

The Product Must Match the Evidence

A study involving 300 milligrams of purified prescription-grade CBD does not automatically support a sleep claim for a gummy containing 10 milligrams of CBD alongside melatonin and several herbs.

Important differences may include:

• Isolated CBD versus full-spectrum extract

• Oral, inhaled or topical delivery

• Single versus repeated dosing

• Amount of CBD

• THC and other cannabinoid content

• Participant age and health

• Diagnosed condition versus a healthy population

• Prescription-grade versus retail formulation

Companies should not borrow a finding from one ingredient, dose or formulation and present it as proof for a materially different finished product.

Statistical Significance Is Not the Same as Meaningful Benefit

A result can be statistically significant but too small to justify the advertised promise.

For example, a modest change on a questionnaire may not support statements such as:

• “Sleep through the night”

• “Wake fully refreshed”

• “Works in minutes”

• “Clinically proven insomnia relief”

The size and practical meaning of the result should match the strength of the wording.

Evidence That Is Usually Insufficient on Its Own

The following may contribute to scientific understanding but generally do not independently establish a human health benefit:

• Laboratory or cell studies

• Animal experiments

• Mechanistic theories

• Customer surveys

• Testimonials

• Uncontrolled observations

• Narrative reviews

• Studies of unrelated cannabinoids

• Research using a materially different dose or product

Testimonials describe experiences. They do not prove that the product caused those experiences.

What Operation CBDeceit Demonstrated

In December 2020, the FTC announced Operation CBDeceit, involving six sellers accused of making unsupported claims that CBD products could treat serious diseases and health conditions.

The advertised conditions included cancer, heart disease, hypertension and Alzheimer’s disease. The proposed orders restricted future claims, required appropriate human clinical testing or other competent and reliable evidence, and imposed monetary payments on five companies ranging from $20,000 to $85,000. Several companies were also required to notify consumers of the FTC orders.

The FTC brought another CBD case in 2021 involving alleged claims related to conditions including cancer and multiple sclerosis.

These actions demonstrate that:

• Advertising alone can create enforcement exposure.

• A product does not need to be contaminated before its marketing becomes unlawful.

• Consumer notification may be required.

• Future claims may become subject to binding restrictions.

• Testimonials and implied messaging receive regulatory attention.

• Small businesses are not exempt from substantiation requirements.

FDA also maintains a public list of warning letters involving cannabis-derived products, which businesses can review for practical examples of problematic claims.

How to Write More Responsible CBD Benefit Statements

There is no list of words that automatically makes a CBD claim compliant. Phrases such as “supports”, “promotes” and “helps maintain” may sound cautious, but they still communicate objective health benefits requiring substantiation.

Context also matters. “Supports restful sleep” beside a page discussing chronic insomnia may imply treatment of the disorder.

High-Risk Wording

Avoid unapproved statements such as:

• Treats insomnia

• Reduces arthritis pain

• Relieves anxiety disorders

• Prevents seizures

• Fights cancer

• Reduces inflammation throughout the body

• Replaces prescription pain medicine

• Doctor recommended for depression

• Clinically proven to work immediately

Potentially Lower-Risk Factual Statements

When accurate and adequately supported, businesses may focus on verifiable product attributes such as:

• Contains 20 mg of labelled CBD per serving

• Made with hemp-derived ingredients

• Batch tested by an independent laboratory

• Certificate of analysis available for this batch

• THC result below the stated laboratory reporting limit

• Fragrance-free

• Vegan ingredients

• Intended for topical cosmetic use

• Full ingredient list available

Even factual claims require proof. “THC-free”, “organic”, “non-toxic”, “fast-acting”, “maximum strength” and “pharmaceutical grade” all communicate testable facts and should not be used loosely.

Do Not Turn General Education Into Product Advertising

A company may publish educational content, but separation requires more than adding “for information only”.

Risk increases when an article:

• Names a disease in the title

• Describes CBD as an effective treatment

• Links directly to a product

• Uses repeated purchase prompts

• Selectively cites favourable research

• Omits limitations and safety information

• Is written or paid for by the product manufacturer without disclosure

Educational content should accurately represent the evidence and make commercial relationships transparent.

Our guide to choosing safer wellness products online explains why consumers should examine testing, ingredients, labels and retailer transparency rather than relying on promotional claims.

💡 Expert Tip: Read every claim together with the page title, images, testimonials and call-to-action. If the combined message sounds stronger than the individual sentence, regulate the combined message—not just the sentence.

Control Testimonials, Reviews and Affiliate Marketing

A customer review can become part of a company’s advertising when the business selects, edits, promotes or republishes it.

A testimonial such as “This cured my fibromyalgia” can create a disease claim even when the customer originally wrote it without prompting. Republishing it does not transform it into protected personal opinion.

The FTC’s endorsement guidance also explains that “results not typical” and “individual results may vary” generally do not correct a misleading impression about what consumers can expect.

Businesses should:

• Avoid featuring disease-treatment testimonials.

• Verify that endorsements reflect genuine experiences.

• Never purchase or fabricate reviews.

• Disclose payments, free products and affiliate relationships.

• Provide affiliates with written claim rules.

• Monitor influencer, affiliate and publisher content.

• Require correction or removal of non-compliant claims.

• Retain records showing monitoring and enforcement.

A paid influencer’s unsupported claim may expose both the influencer and the advertiser. Material connections should be disclosed clearly with the endorsement—not buried in a profile, hashtag cluster or separate webpage.

Use CBD Labels and Laboratory Reports Transparently

A certificate of analysis can help demonstrate what a laboratory found in a particular sample. It does not prove that the product is effective, safe for everyone or compliant with every applicable law.

A useful COA should be:

• Issued by an identifiable independent laboratory

• Matched to the current batch or lot

• Dated

• Accessible before purchase

• Clear about the tested sample

• Consistent with the product label

• Complete rather than selectively cropped

• Inclusive of relevant cannabinoid and contaminant results

Depending on the product and jurisdiction, testing may address:

• CBD and THC concentration

• Other cannabinoids

• Heavy metals

• Pesticides

• Residual solvents

• Microbial contamination

• Mycotoxins

Businesses should avoid saying “FDA approved”, “FDA certified” or “FDA tested” unless that statement is specifically and demonstrably true. Routine retail CBD products are not FDA-approved medicines.

Product labels should also accurately state identity, quantity, ingredients, business details, directions, warnings and any information required under the applicable federal and state framework.

Clear ingredients, batch details and appropriately qualified claims allow consumers and commercial partners to evaluate a product more accurately.

Why Marketing Copy Affects Payment and Platform Approval

Compliance reviews are not limited to regulators.

Banks, insurers, advertising platforms, marketplaces and payment providers may review:

• Product categories

• Website claims

• Lab reports

• Licences

• Refund and subscription policies

• Shipping jurisdictions

• Chargeback history

• Age restrictions

• Affiliate practices

Providers supporting payment processing for cbd merchants may apply underwriting requirements that are separate from FDA or FTC rules.

Removing disease claims may reduce one source of risk, but it does not guarantee approval. Commercial platforms can impose policies stricter than the legal minimum, and those policies may change.

A company should never describe processor approval as proof that the product is lawful, clinically effective or endorsed by a regulator.

Audit Everything Customers Can See

A compliance audit should cover more than labels and product pages.

Review:

• Homepage copy

• Product names and descriptions

• Blog articles

• Category pages

• FAQs

• Website search results

• Page titles and meta descriptions

• Image alt text

• Structured data

• Email campaigns

• SMS messages

• Paid-search advertisements

• Social-media content

• Influencer posts

• Affiliate articles

• Marketplace listings

• Customer reviews selected for display

• Packaging inserts

• Sales scripts

• Downloadable guides

• Archived pages still accessible online

Old content can remain indexed, shared or archived long after the company changes its main website.

Build a Substantiation File for Every Claim

Each objective claim should have a record containing:

• The exact wording

• Where it appears

• The intended consumer interpretation

• The evidence relied upon

• An independent expert assessment where appropriate

• Product, dose and formulation comparison

• Study limitations

• Required qualifications or disclosures

• Approval date

• Reviewer’s name

• Next review date

• Versions used by affiliates or distributors

A folder filled with studies is not the same as a substantiation file. The business must

explain why the evidence supports the exact claim consumers will see.

Create a Pre-Publication Approval Gate

Every customer-facing claim should pass through one documented approval process.

A practical workflow is:

1. Classify the product. Confirm its intended use and legal category.

2. Map the jurisdictions. Identify where the product will be advertised and sold.

3. Write the proposed claim. Include images and surrounding context.

4. Define the net impression. Record what a reasonable customer is likely to understand.

5. Review the evidence. Check population, product, dose and outcome.

6. Assess FDA risk. Determine whether the claim creates drug intended use or another product-category problem.

7. Assess FTC risk. Confirm that the claim is truthful, non-misleading and adequately substantiated.

8. Check state requirements. Review cannabinoid, labelling and advertising rules.

9. Approve and archive. Record the final wording and evidence.

10. Monitor after publication. Review affiliates, customer responses and regulatory changes.

Begin with the oldest live material. Legacy blog posts and forgotten landing pages frequently contain the strongest disease claims.

Frequently Asked Questions

Can a CBD business call its product a dietary supplement?

FDA currently maintains that CBD products cannot lawfully be marketed federally as dietary supplements. State permission to sell a product does not automatically change this federal position.

Does the standard FDA disclaimer make a CBD claim compliant?

No. The disclaimer does not legalise CBD as a dietary-supplement ingredient, correct an unsupported statement or neutralise a disease-treatment claim.

Is “supports restful sleep” a safe CBD claim?

Not automatically. It remains an objective health-related claim requiring evidence, and its context may imply treatment of insomnia.

Can a CBD brand cite research about Epidiolex?

A business may discuss the approved drug accurately in genuinely educational content. It should not imply that an over-the-counter CBD product is equivalent to Epidiolex or has the same approved benefits.

Are customer reviews protected because customers wrote them?

Not necessarily. Reviews may become advertising when a company selects, promotes, edits or republishes them. Disease claims should not be featured as product endorsements.

Does third-party testing prove that CBD works?

No. Testing may verify cannabinoid content or selected contaminants in a sample. It does not establish clinical effectiveness.

Can a business use animal or laboratory research?

Such research may be discussed accurately with appropriate context, but it generally cannot substantiate a claim that a retail product produces a health benefit in humans.

Can an influencer make claims the brand cannot make?

No. Brands should train and monitor influencers. Both the advertiser and influencer may face exposure for misleading claims or inadequate sponsorship disclosure.

Are CBD rules the same in every state?

No. States apply different rules covering permitted products, THC thresholds, age limits, testing, packaging, registration and marketing. Legal review should cover every sales jurisdiction.

Continue Exploring CBD Wellness

Responsible CBD communication requires realistic claims, transparent testing and clear discussion of uncertainty. Explore our CBD Wellness Hub for evidence-informed articles about cannabinoids, product safety and consumer decision-making.

Final Thoughts

Responsible CBD marketing is not simply a matter of replacing “treats” with “supports”.

Businesses must first understand whether the product itself can lawfully be marketed. They must then evaluate the full advertising message and possess evidence matching the specific formulation, dose, audience and promised effect.

Clear labels, current laboratory reports and conservative wording can support consumer trust. They cannot substitute for product legality, adequate scientific substantiation or proper legal review.

References

• FDA — Regulation of Cannabis and Cannabis-Derived Products

• FDA — What to Know About Products Containing Cannabis and CBD

• FDA — Cannabis-Derived Product Warning Letters

• FTC — Health Products Compliance Guidance

• FTC — Operation CBDeceit

• FTC — Endorsement Guides